You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CCR2i

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Inflammation Trial in Saint Louis (64Cu-DOTA-ECL1i)

Recruiting
  • Lung Inflammation
  • Saint Louis, Missouri
    Washington University School of Medicine
Oct 3, 2022

Heart Diseases Trial in Saint Louis (64Cu-DOTA-ECL1i)

Recruiting
  • Heart Diseases
  • Saint Louis, Missouri
    Washington University School of Medicine
Nov 22, 2022

Carotid Atherosclerosis Trial in Saint Louis (Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine), Group 2 64CU-DOTA-ECL1i

Recruiting
  • Carotid Atherosclerosis
  • Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)
  • Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)
  • Saint Louis, Missouri
    Washington University CCIR
Nov 29, 2021

Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma Trial in Baltimore (Stereotactic Body

Recruiting
  • Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
  • Pancreatic Ductal Adenocarcinoma
  • Stereotactic Body Radiation (SBRT)
  • +3 more
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Jan 28, 2022

Head Neck Cancer Trial in Saint Louis (64Cu-DOTA-ECL1i)

Recruiting
  • Head and Neck Cancer
  • Saint Louis, Missouri
    Washington University School of Medicine
Dec 7, 2021

Abdominal Aortic Aneurysm (AAA) Trial in Saint Louis (Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of

Terminated
  • Abdominal Aortic Aneurysm (AAA)
  • Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of 64Cu-DOTA-ECL1i
  • AAA Group- PET-CT imaging with injection of 64Cu-DOTA-ECL1i
  • Saint Louis, Missouri
    Washington University School of Medicine
Apr 9, 2022

Pancreatic Ductal Adenocarcinoma Trial in Saint Louis (BMS-813160, Nivolumab, Gemcitabine)

Active, not recruiting
Has Results
  • Pancreatic Ductal Adenocarcinoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Dec 8, 2022

Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell

Recruiting
  • Recurrent Adult T-Cell Leukemia/Lymphoma
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 18, 2022

HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma Trial in United States (procedure, drug,

Recruiting
  • HIV Infection
  • +10 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +7 more
  • La Jolla, California
  • +3 more
Dec 7, 2022

Abdominal Aortic Aneurysm (AAA), No Abdominal Aortic Aneurysm (Non-AAA) Trial in Saint Louis (AAA Group (Aim 3A), Non-AAA Group,

Recruiting
  • Abdominal Aortic Aneurysm (AAA)
  • No Abdominal Aortic Aneurysm (Non-AAA)
  • AAA Group (Aim 3A)
  • +4 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 11, 2022

CCR5, Microsatellite Stable, Metastatic Trial (700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at

Withdrawn
  • CCR5
  • +3 more
  • 700mg leronlimab weekly dose
  • +3 more
  • (no location specified)
Feb 15, 2023

Rectal Cancer Trial in Frankfurt (drug, radiation, procedure)

Recruiting
  • Rectal Cancer
  • Kineret 100 MG in 0.67 ML Prefilled Syringe
  • +3 more
  • Frankfurt, Germany
    University Hospital Goethe University Frankfurt
Aug 23, 2022

Postmenopausal Osteoporosis Trial in Worldwide (FKS518, US-licensed Prolia)

Active, not recruiting
  • Postmenopausal Osteoporosis
  • Sofia, Sofia City, Bulgaria
  • +75 more
Aug 29, 2022

Metastatic Colorectal Cancer, MSS Trial in Heidelberg (Pembrolizumab, Maraviroc)

Completed
Has Results
  • Metastatic Colorectal Cancer
  • MSS
  • Heidelberg, Germany
    National Center for Tumor Diseases, University Hospital Heidelbe
May 17, 2022

Hand Eczema Trial in Worldwide (Ruxolitinib cream, Vehicle)

Withdrawn
  • Hand Eczema
  • Phoenix, Arizona
  • +48 more
Nov 14, 2022

Pain, Osteo Arthritis Knee, Knee Osteoarthritis Trial in Worldwide (LEVI-04, Placebo:)

Recruiting
  • Pain
  • +6 more
  • Brno, Czechia
  • +12 more
Nov 9, 2022

COVID-19, SARS-CoV2 Infection Trial in India (Candesartan Cilexetil, Repagermanium, Candesartan Placebo)

Recruiting
  • COVID-19
  • SARS-CoV2 Infection
  • Candesartan Cilexetil
  • +3 more
  • Guntur, India
  • +4 more
Mar 13, 2022

Psoriatic Arthritis Trial in Worldwide (PF-06700841, Placebo)

Completed
Has Results
  • Psoriatic Arthritis
  • Maroochydore, Queensland, Australia
  • +47 more
Aug 2, 2021

Episodic Migraine Trial in Worldwide (Atogepant 60 mg, Placebo)

Completed
  • Episodic Migraine
  • Atogepant 60 mg
  • Placebo
  • Colton, California
  • +113 more
Aug 12, 2022

NSCLC, Hepatocellular Carcinoma Trial in New York (Nivolumab, BMS-813160, BMS-986253)

Recruiting
  • Non-small Cell Lung Cancer
  • Hepatocellular Carcinoma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Oct 14, 2021

Advanced Solid Tumors Trial in Canada, Singapore, United States (BAY3375968, Pembrolizumab)

Not yet recruiting
  • Advanced Solid Tumors
  • Chicago, Illinois
  • +4 more
Sep 9, 2022

AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma Trial run by the

Active, not recruiting
  • AIDS-Related Burkitt Lymphoma
  • +5 more
  • Bethesda, Maryland
    NCI Lymphoid Malignancies Branch
Jul 31, 2022

(NIS) on Sodium-glucose Co-transporter-2 Inhibitors Use in

Not yet recruiting
  • Diabetes Mellitus, Type 2
  • Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
  • (no location specified)
May 22, 2023

Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis Trial in Worldwide (Humira 40 MG in Prefilled Syringe, Hulio

Recruiting
  • Moderate Chronic Plaque Psoriasis
  • Severe Chronic Plaque Psoriasis
  • Humira 40 MG in Prefilled Syringe
  • Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe
  • Dupnitsa, Bulgaria
  • +34 more
Jan 18, 2023

Primary Breast Cancer Trial (SPECT)

Not yet recruiting
  • Primary Breast Cancer
  • (no location specified)
Jun 19, 2023